Oxaliplatin-induced immune pancytopenia.
Détails
ID Serval
serval:BIB_B1F2487EC721
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Oxaliplatin-induced immune pancytopenia.
Périodique
Transfusion
ISSN
0041-1132 (Print)
ISSN-L
0041-1132
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
45
Numéro
5
Pages
704-708
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article Publication Status: ppublish
Résumé
BACKGROUND: Oxaliplatin, a third-generation platinum compound, has been implicated in isolated cases of immune hemolytic anemia and/or immune thrombocytopenia. The first case of severe immune pancytopenia related to oxaliplatin is described.
PATIENT AND METHODS: A 79-year-old woman with colorectal cancer was initially treated with 5-fluorouracil and she later received oxaliplatin and leucovorin every 2 to 4 weeks. During the 15th and 17th cycles of chemotherapy she developed thrombocytopenia, hemolysis, and neutropenia. No problems occurred during the 16th cycle without oxaliplatin. Serologic testing including detection of drug-dependent antibodies and autoantibodies was performed with standard techniques.
RESULTS: Serologic findings included a positive immunoglobulin G direct antiglobulin test; nonreactive red blood cell (RBC) eluates; platelet (PLT)-bound antibodies to glycophorin (GP) IIb-IIIa, GPIb-IX, and GPIa-IIa; and oxaliplatin-dependent antibodies to PLTs, RBCs, and neutrophils.
CONCLUSION: Oxaliplatin may lead to the production of ddabs to RBCs, PLTs, and neutrophils. Thus the risk of immune cytopenias should always be considered in patients treated with oxaliplatin.
PATIENT AND METHODS: A 79-year-old woman with colorectal cancer was initially treated with 5-fluorouracil and she later received oxaliplatin and leucovorin every 2 to 4 weeks. During the 15th and 17th cycles of chemotherapy she developed thrombocytopenia, hemolysis, and neutropenia. No problems occurred during the 16th cycle without oxaliplatin. Serologic testing including detection of drug-dependent antibodies and autoantibodies was performed with standard techniques.
RESULTS: Serologic findings included a positive immunoglobulin G direct antiglobulin test; nonreactive red blood cell (RBC) eluates; platelet (PLT)-bound antibodies to glycophorin (GP) IIb-IIIa, GPIb-IX, and GPIa-IIa; and oxaliplatin-dependent antibodies to PLTs, RBCs, and neutrophils.
CONCLUSION: Oxaliplatin may lead to the production of ddabs to RBCs, PLTs, and neutrophils. Thus the risk of immune cytopenias should always be considered in patients treated with oxaliplatin.
Mots-clé
Aged, Antineoplastic Agents/adverse effects, Colorectal Neoplasms/drug therapy, Female, Hemolysis, Humans, Neutropenia/chemically induced, Neutropenia/immunology, Organoplatinum Compounds/adverse effects, Pancytopenia/chemically induced, Pancytopenia/immunology, Thrombocytopenia/chemically induced, Thrombocytopenia/immunology
Pubmed
Web of science
Création de la notice
09/11/2014 18:31
Dernière modification de la notice
20/08/2019 16:20